Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS) and Insmed (INSM)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hims & Hers Health (HIMS – Research Report) and Insmed (INSM – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hims & Hers Health (HIMS)
Truist Financial analyst Jailendra Singh maintained a Hold rating on Hims & Hers Health today. The company’s shares closed last Thursday at $15.82, close to its 52-week low of $11.20.
According to TipRanks.com, Singh has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Hims & Hers Health is a Hold with an average price target of $32.39, which is a 102.3% upside from current levels. In a report issued on February 5, Needham also maintained a Hold rating on the stock.
See the top stocks recommended by analysts >>
Insmed (INSM)
In a report released today, Danielle Brill from Truist Financial maintained a Buy rating on Insmed. The company’s shares closed last Thursday at $161.00.
According to TipRanks.com, Brill is a 5-star analyst with an average return of
Currently, the analyst consensus on Insmed is a Strong Buy with an average price target of $217.71, implying a 41.6% upside from current levels. In a report issued on February 6, Evercore ISI also maintained a Buy rating on the stock with a $208.00 price target.
